RT Conference Proceedings
T1 Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
A1 Owonikoko, T. K.
A1 Kim, H. R.
A1 Govindan, R.
A1 Ready, N.
A1 Reck, M.
A1 Peters, S.
A1 Dakhil, S. R.
A1 Navarro, A.
A1 Rodriguez-Cid, J.
A1 Schenker, M.
A1 Lee, J. S.
A1 Gutierrez, V.
A1 Percent, I.
A1 Morgensztern, D.
A1 Fairchild, J.
A1 Baudelet, C.
A1 Park, K.
PB Oxford univ press
SN 0923-7534
YR 2019
FD 2019-04-01
LK https://hdl.handle.net/10668/24385
UL https://hdl.handle.net/10668/24385
LA en
DS RISalud
RD Apr 6, 2025